Palisade Bio (PALI) News Today $2.00 +0.32 (+19.05%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$2.10 +0.10 (+4.80%) As of 07:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PALI Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Palisade Bio Closes $138 Million Public Offering to Advance PALI-2108 for Ulcerative Colitis DevelopmentOctober 2, 2025 | quiverquant.comQPalisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment OptionOctober 2, 2025 | globenewswire.comPalisade Bio Stock Climbs To 9-Month High After $120M Stock Offering; Retail Sees More Gains AheadOctober 2, 2025 | msn.comPalisade Bio prices 171.4M shares at 70c in upsized underwritten public offeringOctober 1, 2025 | msn.comPalisade Bio, Inc. Announces Pricing of Public Offering of Common Stock Expected to Raise Approximately $120 MillionOctober 1, 2025 | quiverquant.comQPalisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common StockOctober 1, 2025 | globenewswire.comPalisade Bio files to sell 147.1M shares of common stockSeptember 29, 2025 | msn.comPalisade Bio Adjourns Stockholder Meeting Due to QuorumSeptember 26, 2025 | tipranks.comPalisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of QuorumSeptember 26, 2025 | globenewswire.comPalisade Bio Reschedules Stockholder Meeting Due to Quorum IssueSeptember 18, 2025 | tipranks.comPalisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of QuorumSeptember 18, 2025 | globenewswire.comPalisade Bio reports results from PALI-2108 Phase 1b dataSeptember 17, 2025 | msn.comPalisade Bio Reports Positive PALI-2108 Phase 1b Clinical DataSeptember 17, 2025 | globenewswire.comHealth Canada clears Palisade Bio’s trial of Crohn’s disease treatmentSeptember 8, 2025 | finance.yahoo.comPalisade Bio receives Health Canada clearance for Phase 1b PALI-2108 trialSeptember 6, 2025 | msn.comPalisade Bio receives Health Canada clearance for Phase 1b PALI-2108 trialSeptember 6, 2025 | msn.comPalisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)September 6, 2025 | markets.businessinsider.comPalisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)September 6, 2025 | markets.businessinsider.comPalisade Bio Advances PALI-2108 as First Dual-Acting Therapy for Fibrostenotic Crohn's Disease, Dosing to Begin H2 2025September 5, 2025 | quiverquant.comQPalisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)September 5, 2025 | globenewswire.comPalisade Bio releases virtual KOL Connect segment on PALI-2108August 25, 2025 | msn.comPalisade Bio Features Dr. Brian Feagan in Discussion on Fibrostenotic Crohn's Disease and Innovations in IBD Treatment with PALI-2108August 25, 2025 | quiverquant.comQPalisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108August 25, 2025 | globenewswire.comPalisade Bio files to sell 8.9M shares of common stock for holdersAugust 16, 2025 | msn.comPalisade reports outcomes from Phase Ib ulcerative colitis studyAugust 11, 2025 | finance.yahoo.comPalisade Bio’s PALI-2108: A Promising New Treatment for Ulcerative ColitisAugust 8, 2025 | msn.comPalisade Bio Reports Positive Phase 1b Data for PALI-2108 in Ulcerative Colitis Demonstrating Safety and EfficacyAugust 7, 2025 | quiverquant.comQPalisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108August 7, 2025 | globenewswire.comPalisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in ChinaJuly 31, 2025 | globenewswire.comPalisade Bio’s Phase 1 Study on PALI-2108: A New Hope for Ulcerative Colitis TreatmentJuly 30, 2025 | tipranks.comPalisade Bio, Inc. Announces Agreement to Exercise Existing Warrants and Raise Approximately $3.9 MillionJuly 23, 2025 | quiverquant.comQPalisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 23, 2025 | finance.yahoo.comPalisade Bio Announces Exercise of Previously Issued Warrants for $3.9 MillionJuly 23, 2025 | finance.yahoo.comPalisade Bio Announces Exercise of Previously Issued Warrants for $3.9 MillionJuly 23, 2025 | globenewswire.comPalisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comPalisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of ...July 11, 2025 | morningstar.comMPalisade Bio, Inc. Appoints Dr. Emil Chuang to Board of ... - NasdaqJuly 11, 2025 | nasdaq.comPalisade Bio appoints to its Board of DirectorsJuly 9, 2025 | msn.comPalisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of DirectorsJuly 9, 2025 | globenewswire.comPalisade Bio Reports Improved Quarterly LossesJune 2, 2025 | tipranks.comPalisade Bio, Inc.: Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn ...May 28, 2025 | finanznachrichten.dePalisade Bio reports positive Phase 1 results for new drugMay 28, 2025 | investing.comPalisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and ...May 28, 2025 | morningstar.comMPalisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative ColitisMay 27, 2025 | globenewswire.comPalisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel DiseasesMay 6, 2025 | globenewswire.comPalisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease SummitMay 1, 2025 | globenewswire.comHyundai’s Next-Gen Hybrid System Offers 45% Boost In Fuel EfficiencyApril 21, 2025 | msn.comPalisade completes dosing in Phase 1b portion of Phase 1a/1n study of PALI-2108April 9, 2025 | markets.businessinsider.comPalisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108April 9, 2025 | globenewswire.comMaxim Group Sticks to Their Buy Rating for Palisade Bio (PALI)March 27, 2025 | markets.businessinsider.com Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PALI Media Mentions By Week PALI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PALI News Sentiment▼0.900.63▲Average Medical News Sentiment PALI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PALI Articles This Week▼21▲PALI Articles Average Week Get the Latest News and Ratings for PALI and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Palisade Bio and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies HYPD News ALGS News ICCC News DRRX News ACRV News GNTA News SKYE News TELO News CUE News TLPH News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PALI) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
